Thursday, July 03, 2008
Cardiovascular Outcomes Among Sildenafil Users
Conclusions
The results of the IMHS constitute a valuable contribution to the literature on real-world data on users of sildenafil. Instead of evaluating CVD events in men enrolled in clinical trials, the IMHS included men in the general population who were prescribed sildenafil. The results are consistent with previous analyses, suggesting that the incidence of CVD events in men prescribed sildenafil for ED was low and similar to those in clinical trials and the UK PEM study. The results also support previous reports that ED and CVD share risk factors and that men with ED are at greater risk for CVD events than those without ED.
CLICK HERE for subscription information about this journal. Printer- Friendly Email ThisFunding Information
The study was sponsored by Pfizer Inc. Murray A. Mittleman has served as a consultant to Pfizer Inc., Lily ICOS LLC and Bayer Healthcare, and has previously received research funding from Pfizer Inc. Statistical support was provided by Xiaofeng Zhou of Pfizer Inc. Editorial support was provided by Carl Clay, PhD, and Deborah M. Campoli-Richards, BSPHA, RPh, at Complete Healthcare Communications, Inc., and was funded by Pfizer Inc.Reprint Address
Dr Murray A. Mittleman, Cardiovascular Division, Beth Israel Deaconess Medical Center, 330 Brookline Ave - MASCO 423, Boston, MA 02215, USA, Tel.: + 617 632 7694, Fax: + 617 632 7698, Email: mailto:mmittlem@hsph.harvard.edu
Int J Clin Pract. 2008;62(3):367-373. ©2008 Blackwell Publishing
This is a part of article Cardiovascular Outcomes Among Sildenafil Users Taken from "Erectile Disfunction Medication" Information Blog
Labels: pharmacology
